IL10 and acute respiratory distress syndrome: MSCs also increased plasma IL-10 concentrations compared with control group at 48 h (p = 0.043) and 72 h (p = 0.029), significantly (Fig. 5), so that BMSCs reduced lung injury and inflammation via significant immunomodulatory properties and attenuated the severity of ARDS.